NCT04610658 - Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

March 24, 2023

Study Completion Date

March 24, 2023

Conditions

Small-cell Lung CancerRelapsed Small Cell Lung CancerRecurrent Small Cell Lung Cancer

Interventions

DRUG

Nivolumab

Participants will receive 1 mg/kg Nivolumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 treatment cycles, Nivolumab will be continued at a flat dose of 360 mg.

DRUG

Ipilimumab

Participants will receive 3mg/kg Ipilimumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 cycles, Ipilimumab will be discontinued.

DRUG

Lurbinectedin

Participants will be treated at 1 of 3 dose levels of Lurbinectedin, beginning at 1.5 mg/m\^2 and increasing to 3.2 mg/m\^2 or the Maximum Tolerated Dose (MTD)

Trial Locations (2)

33612

Moffitt Cancer Center, Tampa

34747

Advent Health - Celebration, Kissimmee